Pulmatrix (PULM) Cash & Equivalents (2013 - 2026)

Pulmatrix has reported Cash & Equivalents for 14 years, with the latest figure at $3.3 million in Q1 2026.

• Quarterly Cash & Equivalents fell 56.88% year-over-year to $3.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.3 million (down 56.88% YoY) and the FY2025 annual result came in at $4.1 million, down 57.06% from the prior year.
• Cash & Equivalents slipped to $3.3 million in Q1 2026 per PULM's latest filing, from $4.1 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $47.5 million in Q1 2022 and troughed at $3.3 million in Q1 2026.
• A 5-year average of $19.9 million and a median of $16.3 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2025: Cash & Equivalents fell 23.94% in 2022, then sank 57.06% in 2025.
• Over 5 years, Cash & Equivalents stood at $35.6 million in 2022, then sank by 46.19% to $19.2 million in 2023, then tumbled by 50.34% to $9.5 million in 2024, then tumbled by 57.06% to $4.1 million in 2025, then fell by 18.69% to $3.3 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $3.3 million, $4.1 million, and $4.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.